Previous 10 | Next 10 |
Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc...
PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that...
NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Context Therapeutics Inc. (NASDAQ: CNTX). The in-depth 26-page initiation report includes detailed information on the...
--News Direct-- Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial. Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating ...
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a ...
Penny Stocks With News Light Up The Scanners This Week This week will likely be one of the most volatile for the overall market. But for anyone trading penny stocks , it’s just another week to try and capitalize on everyday price action. The FOMC meeting begins today with all eyes ...
Context Therapeutics ( NASDAQ: CNTX ) said its clinical trial collaborator Stemline Therapeutics' medicine Orserdu was approved by the U.S. Food and Drug Administration (FDA) to treat a type of breast cancer. Menarini Group's unit Stemline's drug Orserdu (elacestrant) w...
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer ORSERDU is being evaluated in combination with Context’s ONA-XR in the ongoing ELONA trial PHILADELPHIA, Jan. 31, ...
Penny Stocks, News, & Market Momentum This Week This is the first full week of the New Year and one that many investors will be focused on. Not only will we see Federal Reserve Chair Jerome Powell’s first major speech of the year, but there’s also no time wasted for the firs...
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BA...
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
Context Therapeutics Inc. Website:
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...